866-997-4948(US-Canada Toll Free)

Human Papillomavirus Vaccine Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Published By :

Transparency Market Research

Published Date : Mar 2018

Category :

Pharmaceutical

No. of Pages : 212 Pages

Human Papillomavirus Vaccine Market: Overview

This report on the global human papillomavirus vaccine market analyzes the current and future scenario of the global market. Rise in private and public funding for human papillomavirus vaccine, increase in government initiatives to prevent cervical cancer caused by human papillomavirus, growth in prevalence of various cancers caused by human papillomavirus are expected to drive the market during the forecast period.

The global human papillomavirus vaccine market report comprises an elaborate executive summary, which includes market snapshot that provides information about various segments.  It also provides information and data analysis of the global market with respect to segments based on valance, indication, distribution channel, and geography. A detailed qualitative analysis of drivers and restraints, opportunities, and trends have been provided in the market overview section.  Additionally, the section comprises pipeline analysis to help understand the scope in the market. This section also provides market attractiveness analysis in terms of geography and market share analysis by key players, thus providing a thorough analysis of the overall competitive scenario in the global human papillomavirus vaccine market.  

In terms of valence, the market has been divided into Bivalent and Quadrivalent – nonavalent. Quadrivalent, and nonavalent segment is projected to lead the market and is expected to continue its dominance during the forecast period followed by bivalent segment. Launch of new multivalent human papillomavirus and increase in incidences of cervical cancer are likely to propel the segment. Based on indication type, cervical cancer dominated the market, in terms of revenue generated, in 2016 and is anticipated to continue its dominance during the forecast period. Anal cancer was the second largest segment in 2016 and it is likely to continue this trend from 2017 to 2025. In terms of distribution channel, government entities held a dominant share of the market. However, it is anticipated to lose market share during the forecast period owing to public and private alliances such as GAVI that are focused on vaccinating people in developing countries.

Geographically, the global human papillomavirus vaccine market has been categorized into major regions and key countries in the respective regions: North America (the US  and Canada), Europe (Germany, France, Italy, Spain, the UK, and Rest of Europe), Asia Pacific (China, Japan, India, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa).  

The report also profiles major players operating in the global human papillomavirus vaccine market based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments.  Major players profiled in this report include Merck & Co., Inc., GlaxoSmithKline plc. Sanofi, Johnson & Johnson, AstraZeneca, and Serum Institute of India Pvt. Ltd.

The global human papillomavirus vaccine market has been segmented as below:

Global Human Papillomavirus Vaccine Market, by Valence

  • Bivalent
  • Quadrivalent and Nonavalent

Global Human Papillomavirus Vaccine Market, by Indication

  • Cervical Cancer
  • Anal Cancer
  • Vaginal Cancer
  • Penile Cancer
  • Vulvar Cancer
  • Oropharyngeal Cancer
  • Genital Warts
  • Others

Global Human Papillomavirus Vaccine Market, by Distribution Channel

  • Physicians
  • Wholesalers
  • Physician Distributors
  • Government Entities
  • Public and Private Alliances

Global Human Papillomavirus Vaccine Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1.  Preface
1.1. Market Segmentation
1.2. Key Research Objectives
1.3. Research Highlights

2.  Assumptions and Acronyms Used

3. Research Approach & Methodology
3.1. Research Methodology Overview
3.2. Project Initiation
3.3. Secondary Research Methodology
3.4. Primary Research Methodology
3.5. Analysis Research Methodology
3.6. Final Report & Conclusions Research Methodology

4. Executive Summary: Global Human Papillomavirus Vaccine Market

5.  Market Overview
5.1. Overview
5.2. Key Industry Events and Developments
5.3. Global Human Papillomavirus Vaccine Market Forecast and Analysis
5.4. Global Human Papillomavirus Vaccine Market Outlook

6. Market Dynamics
6.1. Drivers and Restraints Snapshot Analysis
6.2. Drivers
6.3. Restraints
6.4. Opportunity
6.5. Key Trends
6.6. Institutional Sales Overview, by Volume (No. of Unit Dose)
6.7. Pricing Analysis
6.8. Pipeline Analysis: Human Papillomavirus Vaccine

7. Global Human Papillomavirus Vaccine Market Analysis and Forecasts, by Valence
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast by Valence, 2015–2025
7.3.1. Bivalent
7.3.2. Quadrivalent, and Nonavalent
7.4. Global Human Papillomavirus Vaccines Market Analysis, by Valence
7.5. Global Human Papillomavirus Vaccines Market Forecast, by Valence
7.6. Global Human Papillomavirus Vaccines Market Analysis, by Valence

8. Global Human Papillomavirus Vaccine Market Analysis and Forecasts, by Indication
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast by Indication, 2015–2025
8.3.1. Cervical Cancer
8.3.2. Anal Cancer
8.3.3. Vaginal Cancer
8.3.4. Penile Cancer
8.3.5. Vulvar Cancer
8.3.6. Oropharyngeal Cancer
8.3.7. Genital Warts
8.3.8. Others
8.4. Global Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
8.5. Global Human Papillomavirus Vaccines Market Forecast, by Indication
8.6. Global Human Papillomavirus Vaccines Market Attractiveness Analysis, by Indication

9. Global Human Papillomavirus Vaccine Market Analysis and Forecasts, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast by Distribution Channel, 2015–2025
9.3.1. Physicians
9.3.2. Wholesalers
9.3.3. Physician Distributors
9.3.4. Government Entities
9.3.5. Public and Private Alliances
9.4. Global Human Papillomavirus Vaccines Market Analysis, by Distribution Channel
9.5. Global Human Papillomavirus Vaccines Market Forecast, by Distribution Channel
9.6. Global Human Papillomavirus Vaccines Market Analysis, by Distribution Channel

10. Global Human Papillomavirus Vaccine Market Analysis and Forecasts, by Region
10.1. Global Human papillomavirus vaccine Market Snapshot, by Country
10.2. Global Human Papillomavirus Vaccines Market Analysis, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Global Human Papillomavirus Vaccines Market Forecast, by Region
10.4. Global Human Papillomavirus Vaccines Market Attractiveness Analysis, by Region

11. North America Human Papillomavirus Vaccine Market Analysis
11.1. Policies and Regulations
11.2. Key Findings
11.3. North America Human Papillomavirus Vaccines Market Overview
11.4. North America Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Country
11.4.1. U.S.
11.4.2. Canada
11.5. Market Attractiveness Analysis
11.6. North America Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Valance
11.6.1. Bivalent
11.6.2. Quadrivalent, and Nonavalent
11.7. Market Attractiveness Analysis
11.8. North America Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
11.8.1. Cervical Cancer
11.8.2. Anal Cancer
11.8.3. Vaginal Cancer
11.8.4. Penile Cancer
11.8.5. Vulvar Cancer
11.8.6. Oropharyngeal Cancer
11.8.7. Genital Warts
11.8.8. Others
11.9. Market Attractiveness Analysis
11.10. Market Value Share Analysis by Distribution Channel, 2015–2025
11.10.1. Physicians
11.10.2. Wholesalers
11.10.3. Physician Distributors
11.10.4. Government Entities
11.10.5. Public and Private Alliances

12. Europe Human Papillomavirus Vaccine Market Analysis
12.1. Policies and Regulations
12.2. Key Findings
12.3. Europe Human Papillomavirus Vaccines Market Overview
12.4. Europe Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Country
12.4.1. Germany
12.4.2. France
12.4.3. Italy
12.4.4. Spain
12.4.5. U.K.
12.4.6. Rest of Europe
12.5. Market Attractiveness Analysis
12.6. Europe Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Valance
12.6.1. Bivalent
12.6.2. Quadrivalent, and Nonavalent
12.7. Market Attractiveness Analysis
12.8. Europe Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
12.8.1. Cervical Cancer
12.8.2. Anal Cancer
12.8.3. Vaginal Cancer
12.8.4. Penile Cancer
12.8.5. Vulvar Cancer
12.8.6. Oropharyngeal Cancer
12.8.7. Genital Warts
12.8.8. Others
12.9. Market Attractiveness Analysis
12.10. Market Value Share Analysis by Distribution Channel, 2015–2025
12.10.1. Physicians
12.10.2. Wholesalers
12.10.3. Physician Distributors
12.10.4. Government Entities
12.10.5. Public and Private Alliances

13. Asia Pacific Human Papillomavirus Vaccine Market Analysis
13.1. Policies and Regulations
13.2. Key Findings
13.3. Asia Pacific Human Papillomavirus Vaccines Market Overview
13.4. Asia Pacific Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Country
13.4.1. China
13.4.2. Japan
13.4.3. India
13.4.4. Australia & New Zealand
13.4.5. Rest of Asia Pacific
13.5. Market Attractiveness Analysis
13.6. Asia Pacific Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Valance
13.6.1. Bivalent
13.6.2. Quadrivalent, and Nonavalent
13.7. Market Attractiveness Analysis
13.8. Asia Pacific Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
13.8.1. Cervical Cancer
13.8.2. Anal Cancer
13.8.3. Vaginal Cancer
13.8.4. Penile Cancer
13.8.5. Vulvar Cancer
13.8.6. Oropharyngeal Cancer
13.8.7. Genital Warts
13.8.8. Others
13.9. Market Attractiveness Analysis
13.10. Market Value Share Analysis by Distribution Channel, 2015–2025
13.10.1. Physicians
13.10.2. Wholesalers
13.10.3. Physician Distributors
13.10.4. Government Entities
13.10.5. Public and Private Alliances

14. Latin America Human Papillomavirus Vaccine Market Analysis
14.1. Policies and Regulations
14.2. Key Findings
14.3. Latin America Human Papillomavirus Vaccines Market Overview
14.4. Latin America Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Country
14.4.1. Brazil
14.4.2. Mexico
14.4.3. Rest of Latin America
14.5. Market Attractiveness Analysis
14.6. Latin America Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Valance
14.6.1. Bivalent
14.6.2. Quadrivalent, and Nonavalent
14.7. Market Attractiveness Analysis
14.8. Latin America Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
14.8.1. Cervical Cancer
14.8.2. Anal Cancer
14.8.3. Vaginal Cancer
14.8.4. Penile Cancer
14.8.5. Vulvar Cancer
14.8.6. Oropharyngeal Cancer
14.8.7. Genital Warts
14.8.8. Others
14.9. Market Attractiveness Analysis
14.10. Market Value Share Analysis by Distribution Channel, 2015–2025
14.10.1. Physicians
14.10.2. Wholesalers
14.10.3. Physician Distributors
14.10.4. Government Entities
14.10.5. Public and Private Alliances

15. Middle East & Africa Human Papillomavirus Vaccine Market Analysis
15.1. Policies and Regulations
15.2. Key Findings
15.3. Middle East & Africa Human Papillomavirus Vaccines Market Overview
15.4. Middle East & Africa Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Country
15.4.1. GCC Countries
15.4.2. South Africa
15.4.3. Rest of Middle East & Africa
15.5. Market Attractiveness Analysis
15.6. Middle East & Africa Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Valance
15.6.1. Bivalent
15.6.2. Quadrivalent, and Nonavalent
15.7. Market Attractiveness Analysis
15.8. Middle East & Africa Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
15.8.1. Cervical Cancer
15.8.2. Anal Cancer
15.8.3. Vaginal Cancer
15.8.4. Penile Cancer
15.8.5. Vulvar Cancer
15.8.6. Oropharyngeal Cancer
15.8.7. Genital Warts
15.8.8. Others
15.9. Market Attractiveness Analysis
15.10. Market Value Share Analysis by Distribution Channel, 2015–2025
15.10.1. Physicians
15.10.2. Wholesalers
15.10.3. Physician Distributors
15.10.4. Government Entities
15.10.5. Public and Private Alliances

16. Competition Landscape
16.1. Human Papillomavirus (HPV) Vaccine Sales Analysis
16.2. Competition Matrix
16.3. Human Papillomavirus (HPV) Vaccine Market Share Analysis, by Company
16.4. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
16.4.1. Merck & Co., Inc.
16.4.1.1. Company Description
16.4.1.2. Financial Overview
16.4.1.3. Strategic Overview
16.4.1.4. Recent Developments
16.4.1.5. SWOT ANALYSIS
16.4.2. GlaxoSmithKline plc.
16.4.2.1. Company Description
16.4.2.2. Financial Overview
16.4.2.3. Strategic Overview
16.4.2.4. Recent Developments
16.4.2.5. SWOT ANALYSIS
16.4.3. Sanofi
16.4.3.1. Company Description
16.4.3.2. Financial Overview
16.4.3.3. Strategic Overview
16.4.3.4. SWOT ANALYSIS
16.4.4. Johnson & Johnson
16.4.4.1. Company Description
16.4.4.2. Financial Overview
16.4.4.3. Recent Developments
16.4.4.4. SWOT ANALYSIS
16.4.5. AstraZeneca
16.4.5.1. Company Description
16.4.5.2. Financial Overview
16.4.5.3. Recent Developments
16.4.5.4. SWOT ANALYSIS
16.4.6. Serum Institute of India Pvt. Ltd.
16.4.6.1. Company Description
16.4.6.2. Recent Developments
16.4.6.3. SWOT ANALYSIS
16.4.7. Xiamen Innovax Biotech CO., LTD. (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.)
16.4.7.1. Company Description
16.4.7.2. SWOT ANALYSIS
16.4.8. General Incorporated Foundation, The Chemo- Sero-Therapeutic Research Institute (Kaketsuken)
16.4.8.1. Company Description
16.4.8.2. Recent Developments
16.4.8.3. SWOT ANALYSIS
16.4.9. Bharat Biotech
16.4.9.1. Company Description
16.4.9.2. SWOT ANALYSIS

List of Table

Table 01: Opportunity Map, by Valence 2016
Table 02: Opportunity Map, by Indication 2016
Table 03: Opportunity Map, by Distribution Channel 2016
Table 04: Pipeline Analysis
Table 05: Global Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Valence, 2015–2025
Table 06: Global Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 07: Global Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 08: Global Human Papillomavirus Vaccines Market (US$ Mn) Forecast, by Region, 2015–2025
Table 09: North America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 10: North America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Valance, 2015–2025
Table 11: North America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 12: North America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 13: Europe Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 14: Europe Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Valance, 2015–2025
Table 15: Europe Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 16: Europe Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 17: Asia Pacific Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 18: Asia Pacific Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Valance, 2015–2025
Table 19: Asia Pacific Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 20: Asia Pacific Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 21: Latin America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 22: Latin America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Valance, 2015–2025
Table 23: Latin America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 24: Latin America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 25: Middle East & Africa Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 26: Middle East & Africa Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Valance, 2015–2025
Table 27: Middle East & Africa Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Indication, 2015–2025
Table 28: Middle East & Africa Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 29: Human Papillomavirus (HPV) Vaccine Sales Analysis, 2014 – 2016

List of Chart

Figure 01: Global Human Papillomavirus Vaccines Market, by Valence, Market Size (US$ Mn), 2016 (A)
Figure 02: Global Human Papillomavirus Vaccines Market Revenue (%), by Indication, 2016 (A)
Figure 03: By Valence Revenue (%), 2016
Figure 04: By Indication Opportunity Map, 2016
Figure 05: Vaccine Type Opportunity Map, 2016
Figure 06: Global Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast, 2015–2025
Figure 07: Market Value Share, by Valence (2016)
Figure 08: Market Value Share, by Indication (2016)
Figure 09: Market Value Share, by Distribution Channel (2016)
Figure 10: Market Value Share, by Region (2016)
Figure 11: Global Human Papillomavirus Vaccines Market Value Share, by Valence, 2016 and 2025
Figure 12: Global Human Papillomavirus Vaccines Market Attractiveness, by Valence, 2017–2025
Figure 13: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Bivalent, 2015–2025
Figure 14: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Quadrivalent, and Nonavalent, 2015–2025
Figure 15: Global Human Papillomavirus Vaccines Vaccines Market Value Share Analysis, by Indication, 2016 and 2025
Figure 16: Global Cervical Cancer Market Revenue, US$ Mn, 2017–2025
Figure 17: Global Anal Cancer Market Revenue, US$ Mn, 2017–2025
Figure 18: Global Vaginal Cancer Market Revenue, US$ Mn, 2017–2025
Figure 19: Global Penile Cancer Market Revenue, US$ Mn, 2017–2025
Figure 20: Global Vulvar Cancers Market Revenue, US$ Mn, 2017–2025
Figure 21: Global Oropharyngeal Cancer Market Revenue, US$ Mn, 2017–2025
Figure 22: Global Genital Warts Market Revenue, US$ Mn, 2017–2025
Figure 23: Global Others Market Revenue, US$ Mn, 2017–2025
Figure 24: Global Human Papillomavirus Vaccines Market Attractiveness Analysis, by Indication
Figure 25: Global Human Papillomavirus Vaccines Market Value Share, by Distribution Channel, 2016 and 2025
Figure 26: Global Human Papillomavirus Vaccines Market Attractiveness, by Distribution Channel, 2017–2025
Figure 27: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Wholesalers Vaccines, 2015–2025
Figure 28: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Physicians Vaccines, 2015–2025
Figure 29: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Government Entities Vaccine, 2015–2025
Figure 30: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Physician Distributors Vaccine, 2015–2025
Figure 31: Global Human Papillomavirus Vaccines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Other Vaccines, 2015–2025
Figure 32: Global Human Papillomavirus Vaccines Market Analysis by Region, 2016 and 2025
Figure 33: Global Human Papillomavirus Vaccines Market Attractiveness Analysis, by Region
Figure 34: North America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
Figure 35: North America Human Papillomavirus Vaccines Market Value Share, by Country/Sub-region, 2016 and 2025
Figure 36: North America Human Papillomavirus Vaccines Market Attractiveness, by Country/Sub-region, 2017–2025
Figure 37: North America Human Papillomavirus Vaccines Market Value Share, by Valance, 2016 and 2025
Figure 38: North America Human Papillomavirus Vaccines Market Attractiveness, by Valance, 2017–2025
Figure 39 highlights market value share of the HPV vaccines market in Europe, by indication, for 2016 and 2025.
Figure 39: North America Human Papillomavirus Vaccines Market Value Share, by Indication, 2016 and 2025
Figure 40: North America Human Papillomavirus Vaccines Market Attractiveness, by Indication, 2017–2025
Figure 41: North America Human Papillomavirus Vaccines Market Value Share, by Distribution Channel, 2016 and 2025
Figure 42: North America Human Papillomavirus Vaccines Market Attractiveness, by Distribution Channel, 2017–2025
Figure 43: Europe Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
Figure 44: Europe Human Papillomavirus Vaccines Market Value Share, by Country, 2016 and 2025
Figure 45: Europe Human Papillomavirus Vaccines Market Attractiveness, by Country, 2017–2025
Figure 46: Europe Human Papillomavirus Vaccines Market Value Share, by Valance, 2016 and 2025
Figure 47: Europe Human Papillomavirus Vaccines Market Attractiveness, by Valance, 2017–2025
Figure 48: Europe Human Papillomavirus Vaccines Market Value Share, by Indication, 2015 and 2025
Figure 49: Europe Human Papillomavirus Vaccines Market Attractiveness, by Indication, 2017–2025
Figure 50: Europe Human Papillomavirus Vaccines Market Value Share, by Distribution Channel, 2016 and 2025
Figure 51: Europe Human Papillomavirus Vaccines Market Attractiveness, by Distribution Channel, 2017–2025
Figure 52: Asia Pacific Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
Figure 53: Asia Pacific Human Papillomavirus Vaccines Market Value Share, by Country/Sub-region, 2016 and 2025
Figure 54: Asia Pacific Human Papillomavirus Vaccines Market Attractiveness, by Country/Sub-region, 2017–2025
Figure 55: Asia Pacific Human Papillomavirus Vaccines Market Value Share, by Valance, 2016 and 2025
Figure 56: Asia Pacific Human Papillomavirus Vaccines Market Attractiveness, by Valance, 2017–2025
Figure 57: Asia Pacific Human Papillomavirus Vaccines Market Value Share, by Indication, 2016 and 2025
Figure 58: Asia Pacific Human Papillomavirus Vaccines Market Attractiveness, by Indication, 2017–2025
Figure 59: Asia Pacific Human Papillomavirus Vaccines Market Value Share, by Distribution Channel, 2016 and 2025
Figure 60: Asia Pacific Human Papillomavirus Vaccines Market Attractiveness, by Distribution Channel, 2017–2025
Figure 61: Latin America Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
Figure 62: Latin America Human Papillomavirus Vaccines Market Value Share, by Country/Sub-region, 2016 and 2025
Figure 63: Latin America Human Papillomavirus Vaccines Market Attractiveness, by Country/Sub-region, 2017–2025
Figure 64: Latin America Human Papillomavirus Vaccines Market Value Share, by Valance, 2016 and 2025
Figure 65: Latin America Human Papillomavirus Vaccines Market Attractiveness, by Valance, 2017–2025
Figure 66: Latin America Human Papillomavirus Vaccines Market Value Share, by Indication, 2016 and 2025
Figure 67: Latin America Human Papillomavirus Vaccines Market Attractiveness, by Indication, 2017–2025
Figure 68: Latin America Human Papillomavirus Vaccines Market Value Share, by Distribution Channel, 2016 and 2025
Figure 69: Latin America Human Papillomavirus Vaccines Market Attractiveness, by Distribution Channel, 2017–2025
Figure 70: Middle East & Africa Human Papillomavirus Vaccines Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
Figure 71: Middle East & Africa Human Papillomavirus Vaccines Market Value Share, by Country/Sub-region, 2016 and 2025
Figure 72: Middle East & Africa Human Papillomavirus Vaccines Market Attractiveness, by Country/Sub-region, 2017–2025
Figure 73: Middle East & Africa Human Papillomavirus Vaccines Market Value Share, by Valance, 2016 and 2025
Figure 74: Middle East & Africa Human Papillomavirus Vaccines Market Attractiveness, by Valance, 2017–2025
Figure 75: Middle East & Africa Human Papillomavirus Vaccines Market Value Share, by Indication, 2016 and 2025
Figure 76: Middle East & Africa Human Papillomavirus Vaccines Market Attractiveness, by Indication, 2017–2025
Figure 77: Middle East & Africa Human Papillomavirus Vaccines Market Value Share, by Distribution Channel, 2016 and 2025
Figure 78: Middle East & Africa Human Papillomavirus Vaccines Market Attractiveness, by Distribution Channel, 2017–2025
Figure 79: Human Papillomavirus (HPV) Vaccine Market Share, by Company, 2016

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *